Table 3.
Treatment in each group a
| Treatments | DM with A/SIP | DM with CIP | DM without ILD |
|---|---|---|---|
| Number of patients | 17 | 24 | 16 |
| PSL or other agent alone, n (%) | 3 (18) | 8 (33) | 12 (75)** |
| PSL | 3 | 7 | 11 |
| CNI | 0 | 1 | 0 |
| AZA | 0 | 0 | 1 |
| PSL + other agents, n (%) | 14 (82) | 16 (67) | 3 (19)** |
| CNI | 9 | 13 | 1 |
| MTX | 0 | 0 | 2 |
| IVCY | 0 | 1 | 0 |
| CNI + MZB | 0 | 1 | 0 |
| CNI + IVCY | 3 | 0 | 0 |
| HSCT | 2 | 1 | 0 |
aA/SIP, Acute/subacute interstitial pneumonia; AZA, Azathioprine; CIP, Chronic interstitial pneumonia; CNI, Calcineurin inhibitor (cyclosporine or tacrolimus); DM, Dermatomyositis; HSCT, Hematopoietic stem cell transplant; ILD, Interstitial lung disease; IVCY, Intravenous pulse cyclophosphamide; MTX, Methotrexate; MZB, Mizoribine; PSL, Prednisolone. **P <0.01 compared with DM with A/SIP using Fisher’s exact test.